| Literature DB >> 32396533 |
Andrea Fava1, Jill Buyon2, Chandra Mohan3, Ting Zhang3, H Michael Belmont2, Peter Izmirly2, Robert Clancy2, Jose Monroy Trujillo4, Derek Fine4, Yuji Zhang5,6, Laurence Magder5, Deepak A Rao7, Arnon Arazi8, Celine C Berthier9, Anne Davidson10, Betty Diamond10, Nir Hacohen8, David Wofsy11, William Apruzzese7, Soumya Raychaudhuri12,13,14,15,16, Michelle Petri1.
Abstract
Lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE), has a heterogeneous clinical and pathological presentation. For example, proliferative nephritis identifies a more aggressive disease class that requires immunosuppression. However, the current classification system relies on the static appearance of histopathological morphology, which does not capture differences in the inflammatory response. Therefore, a biomarker grounded in the disease biology is needed in order to understand the molecular heterogeneity of lupus nephritis and identify immunologic mechanism and pathways. Here, we analyzed the patterns of 1000 urine protein biomarkers in 30 patients with active lupus nephritis. We found that patients stratify over a chemokine gradient inducible by IFN-γ. Higher values identified patients with proliferative lupus nephritis. After integrating the urine proteomics with the single-cell transcriptomics of kidney biopsies, we observed that the urinary chemokines defining the gradient were predominantly produced by infiltrating CD8+ T cells, along with natural killer and myeloid cells. The urine chemokine gradient significantly correlated with the number of kidney-infiltrating CD8+ cells. These findings suggest that urine proteomics can capture the complex biology of the kidney in lupus nephritis. Patient-specific pathways could be noninvasively tracked in the urine in real time, enabling diagnosis and personalized treatment.Entities:
Keywords: Autoimmunity; Lupus; Nephrology; Proteomics; Th1 response
Mesh:
Substances:
Year: 2020 PMID: 32396533 PMCID: PMC7406291 DOI: 10.1172/jci.insight.138345
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708